Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:40:45.017Z.
Consensus retrieved: 2026-10-06T08:40:33.266Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:40:45.017Z.
Quote observation: 2026-10-06T15:37:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca6b3f945453907090b614e1109f6f6fce8b12406cb587c45253d0481e46e17d
Forward PE Ratio (N/A) = Dated Quote Price ($5.37) / Consensus Forward EPS ($-6.30)
FORWARD PE RATIO
N/A
Aligos Therapeutics, Inc.
Market Cap
$33.23M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | $33.23M | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.25M | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.76M | 10.96 |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.34M | N/A |
| Accuray Incorporated (ARAY)vs › | $34.48M | N/A |
| Nortech Systems Incorporated (NSYS)vs › | $31.77M | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $31.77M | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.44M | 9.31 |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.15M | N/A |
| BeyondSpring Inc. (BYSI)vs › | $31.26M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $5.37, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-6.30 | $-6.85 – $-5.93 | 5 | n/m |
| 2027-12-31 | $-5.18 | $-6.70 – $-3.86 | 6 | n/m |
| 2028-12-31 | $-2.45 | $-4.92 – $3.76 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
